An interesting snippet from analysts at Morgan Stanely on a not-so-fat result: GLP-1 medications like Ozempic have seen a $340 billion uplift in market value for GLP-1 makers And, offsetting that on the scales, “disrupted” stocks have lost around US$258 billion in market value Analysts noted that consumer interest in the medications has weakened somewhat,
